source
- Beyond Boston: Unlikely cities stake biotech claimsAs Greater Boston’s biotech industry sheds jobs, three unlikely regions are showing promise as up-and-coming hubs.BioPharma Dive · 25d ago↗ source
- A PureTech startup banks $180M for a new IPF drugCelea, backed by investors such as RA Capital and Leaps by Bayer, is making what it says is an improved version of Roche's Esbriet.BioPharma Dive · 29d ago↗ source
- Roche KRAS drug succeeds in head-to-head lung cancer studyThe Phase 3 trial compared Roche’s divarasib with treatments sold by Amgen and Bristol Myers in patients with non-small cell lung cancer.BioPharma Dive · 29d ago↗ source